HST-1011 not checked

HotSpot Therapeutics, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
Main trialPhase 1/2
“This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.”In the company’s words, NCT05662397 on ClinicalTrials.gov
Other names
CBL-B inhibitor

Other drugs for Solid Tumor, Adult

All 2439 drugs for Solid Tumor, Adult

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 31 Dec 2025 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow HST-1011

Following is part of Solo: you see every change to HST-1011 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in